Skip to main content
. 2023 Dec 28;6(4):858–873. doi: 10.20517/cdr.2023.89

Figure 3.

Figure 3

Intrinsic resistance mechanisms affecting tyrosine kinase inhibitor activity in RCC. Bcl-2: B cell lymphoma-2; Bcl-xL: B cell lymphoma-extra large; EZH2: enhancer of zeste homolog 2; PRC2: polycomb repressive complex 2; RCC: renal cell carcinoma.